Novo Nordisk: Q3 Earnings Bust The Cannibalization Myth

Novo Nordisk is rated BUY with a 6–12 month target price of $57.24, implying approximately 34% upside from $42.62. The article says Q3 results eased concerns about oral-product cannibalization, citing a 53% increase in pill sales that drove net patient additions, alongside moderating capital expenditures, expanding free cash flow and Catalent integration.

Analysis

The key question is not whether oral demand is growing, but whether it adds durable, paid patients to Novo Nordisk’s franchise rather than shifting existing users to a lower-value route. A pill-volume increase can coexist with weaker revenue per patient, persistence, or contribution margin; verify net new starts, refill/persistence, realized net pricing, and injectable trends before treating it as proof of market expansion.

Near term, the bullish framing may support NVO sentiment, but the target price is an analyst estimate—not an independently validated valuation case. Over the next 1–3 months, prescription and payer data, supply availability, and management’s cash-flow outlook matter more than headline pill growth. Over 6–18 months, Catalent integration could ease manufacturing constraints, but execution, quality, and regulatory risks could delay any benefit. Conversely, Lilly’s infrastructure spending is not automatically a disadvantage: if capacity converts into reliable supply and attractive returns, it may strengthen LLY’s competitive position despite financing costs.

Contrarian view: investors may be over-crediting route growth while underweighting pricing and mix. A relative-value tilt toward NVO versus LLY is only justified if patient-level data show incremental, persistent demand without material deterioration in net economics. Falsify that thesis if NVO’s net adds or refill rates weaken, net pricing/margins disappoint, or Lilly demonstrates better supply conversion. Verify the scope and comparability of each company’s patient and prescription metrics before positioning.

Key Decisions for Investors

• Do not trade the stated NVO upside target as a standalone catalyst; treat it as a hypothesis pending independent valuation and earnings verification.
• Watch NVO net new patients, refill persistence, realized pricing, injectable trends, and cash conversion alongside oral demand. If these corroborate incremental, durable growth, consider a staged NVO-over-LLY relative-value position; otherwise remain neutral.
• Track Catalent integration milestones, manufacturing quality/regulatory updates, and supply availability over the next 1–3 months; delay assigning structural margin or capacity benefits until execution is evident.
• Reassess the relative thesis if Lilly converts infrastructure investment into stronger supply and commercial performance, or if NVO’s patient growth fails to translate into recurring revenue and cash flow.